Lexeo Therapeutics (LXEO) Current Leases (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Current Leases data on file, last reported at $528000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 75.16% year-over-year to $528000.0; the trailing twelve-month figure through Mar 2026 stood at $528000.0 (down 75.16% YoY), and the FY2025 full-year result was $2.2 million, up 2.71% from the prior year.
• Current Leases slipped to $528000.0 in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.3 million in Q4 2022 to a low of $518000.0 in Q4 2023.
• A 5-year average of $1.1 million and a median of $570000.0 in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases plunged 77.35% in 2023 and surged 305.73% in 2025, its largest moves.
• Tracing LXEO's Current Leases over 5 years: stood at $2.3 million in 2022, then sank by 77.35% to $518000.0 in 2023, then soared by 305.41% to $2.1 million in 2024, then increased by 2.71% to $2.2 million in 2025, then tumbled by 75.52% to $528000.0 in 2026.
• Business Quant data shows LXEO's Current Leases at $528000.0 in Q1 2026, $2.2 million in Q4 2025, and $568000.0 in Q3 2025.